ReviewKidney international reports2020
Narrative Review of Incremental Hemodialysis.
Review in Kidney international reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- The hemodynamic cost of intermittent hemodialysis and systemic organ stunning.Renal failure · 2026Review
- Incremental Hemodialysis Practices and Impact on Survival: Systematic Review and Meta-Analysis.Kidney medicine · 2026Article
- Article
- Trends in Co-morbid Dementia and Chronic Kidney Disease.Journal of general internal medicine · 2025Article
- Economic Considerations of Incremental Hemodialysis.Kidney360 · 2025Article
- ASN Kidney Health Guidance on the Outpatient Management of Patients with Dialysis-Requiring Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Twelve-Month Estimated Glomerular Filtration Rate Trajectory at the Time of Kidney Replacement Therapy Counseling Predicts Dialysis Initiation Within One Year.Journal of clinical medicine · 2025Article
- Longitudinal Changes in Kidney Solute Clearance in a Prospective Cohort of Patients Initiating Chronic Hemodialysis.Kidney international reports · 2024Article
- Innovative Treatments to Counteract Endothelial Dysfunction in Chronic Kidney Disease Patients.Biomedicines · 2024Review
- Dialysis for older adults: why should the targets be different?Journal of nephrology · 2024Review
- Article
- Incremental versus conventional haemodialysis in end-stage kidney disease: a systematic review and meta-analysis.Clinical kidney journal · 2024Article
- Management of Cardiovascular Diseases in Chronic Hemodialysis Patients.Reviews in cardiovascular medicine · 2023Review
- Plant-based diets for CKD patients: fascinating, trendy, but feasible? A green nephrology perspective.Clinical kidney journal · 2023Review
- Australian Workshops on Patients' Perspectives on Hemodialysis and Incremental Start.Kidney international reports · 2023Article
- On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease.Journal of nephrology · 2022Review
- Smoothing transition to dialysis to improve early outcomes after dialysis initiation among old and frail adults-a narrative review.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Review
- Does delivering more dialysis improve clinical outcomes? What randomized controlled trials have shown.Journal of nephrology · 2022Review
- Incremental and Personalized Hemodialysis Start: A New Standard of Care.Kidney international reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prescription of hemodialysis (HD) in patients with incident end-stage kidney disease (ESKD) is fundamentally empirical. The abrupt transition from nondialysis chronic kidney disease (CKD) to thrice-weekly in-center HD of much the same dialysis intensity as in those with prevalent ESKD underappreciates the progressive nature of kidney disease whereby the decline in renal function has been gradual and ongoing-including at the time of HD initiation. Adjuvant pharmacologic treatment (i.e., diuretics, acid buffers, potassium binders), coupled with residual kidney function (RKF), can complement an initial HD regimen of lower intensity. Barriers to less intensive HD in incident ESKD include risk of inadequate clearance of uremic toxins due to variable and unexpected loss of RKF, lack of patient adherence to assessments of RKF or adjustment of HD intensity, increased burden for all stakeholders in the dialysis units, and negative financial repercussions. A stepped dialysis regimen with scheduled transition from time-delineated twice-weekly HD to thrice-weekly HD could represent an effective and safe strategy to standardize incremental HD in patients with CKD transitioning to early-stage ESKD. Patients' adherence and survival as well as other clinical outcomes should be rigorously evaluated in clinical trials before large-scale implementation of different incremental schedules of HD. This review discusses potential benefits of and barriers to alternative dialysis regimens in patients with incident ESKD, with emphasis on twice-weekly HD with pharmacologic therapy, and summarizes in-progress clinical trials of incremental HD schedules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.